Adele F Holloway1, Joanne L Dickinson2, Tristan Joseph Verhoeff3. 1. Tasmanian School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, 7000, Australia. 2. Menzies Institute for Medical Research, College of Health and Medicine, University of Tasmania, Hobart, 7000, Australia. jo.dickinson@utas.edu.au. 3. Menzies Institute for Medical Research, College of Health and Medicine, University of Tasmania, Hobart, 7000, Australia.
Abstract
PURPOSE: ITGA2 encodes the integrin, α2 which mediates metastatic progression, and is a predictor of poor prognosis and chemoresistance in breast cancer. Decreased ITGA2 promoter methylation is implicated as a driver of increased gene expression in aggressive prostate and pancreatic tumours, however the contribution of altered methylation to ITGA2 expression changes in breast tumours has not been examined. METHODS: ITGA2 gene methylation and gene expression was examined in publicly available breast cancer datasets, and ITGA2 promoter methylation was mapped by targeted bisulphite sequencing analysis in breast tumour cell lines. The expression of a putative regulatory long noncoding RNA (lncRNA) was examined by qPCR and its' functionality was investigated using gene knockdown (antisense oligonucleotides) and over expression in breast cancer cell lines. RESULTS: In breast tumours and breast cancer cell lines the ITGA2 promoter is largely unmethylated, with gene expression variable in tumour subtypes, irrespective of promoter methylation. A novel lncRNA (AC025180.1;ENSG00000249899), named herein I2ALR, was identified at the ITGA2 gene locus, and was variably expressed in breast tumours and breast cancer cell subtypes. I2LAR knockdown resulted in upregulation of ITGA2 gene expression, whilst over-expression of I2ALR resulted in downregulation of ITGA2 mRNA. Further, examination of two downstream targets of ITGA2 associated with breast tumor stemness and metastasis (CCND1 and ACLY), revealed concomitant gene expression changes in response to I2ALR modulation. CONCLUSION: I2ALR represents a novel regulatory molecule targeting ITGA2 expression in breast tumours; a finding of significant and topical interest to the development of therapeutics targeting this integrin.
PURPOSE: ITGA2 encodes the integrin, α2 which mediates metastatic progression, and is a predictor of poor prognosis and chemoresistance in breast cancer. Decreased ITGA2 promoter methylation is implicated as a driver of increased gene expression in aggressive prostate and pancreatic tumours, however the contribution of altered methylation to ITGA2 expression changes in breast tumours has not been examined. METHODS: ITGA2 gene methylation and gene expression was examined in publicly available breast cancer datasets, and ITGA2 promoter methylation was mapped by targeted bisulphite sequencing analysis in breast tumour cell lines. The expression of a putative regulatory long noncoding RNA (lncRNA) was examined by qPCR and its' functionality was investigated using gene knockdown (antisense oligonucleotides) and over expression in breast cancer cell lines. RESULTS: In breast tumours and breast cancer cell lines the ITGA2 promoter is largely unmethylated, with gene expression variable in tumour subtypes, irrespective of promoter methylation. A novel lncRNA (AC025180.1;ENSG00000249899), named herein I2ALR, was identified at the ITGA2 gene locus, and was variably expressed in breast tumours and breast cancer cell subtypes. I2LAR knockdown resulted in upregulation of ITGA2 gene expression, whilst over-expression of I2ALR resulted in downregulation of ITGA2 mRNA. Further, examination of two downstream targets of ITGA2 associated with breast tumor stemness and metastasis (CCND1 and ACLY), revealed concomitant gene expression changes in response to I2ALR modulation. CONCLUSION: I2ALR represents a novel regulatory molecule targeting ITGA2 expression in breast tumours; a finding of significant and topical interest to the development of therapeutics targeting this integrin.
Authors: R B Lichtner; A R Howlett; M Lerch; J A Xuan; J Brink; B Langton-Webster; M R Schneider Journal: Exp Cell Res Date: 1998-05-01 Impact factor: 3.905
Authors: Katia Nones; Nic Waddell; Sarah Song; Ann-Marie Patch; David Miller; Amber Johns; Jianmin Wu; Karin S Kassahn; David Wood; Peter Bailey; Lynn Fink; Suzanne Manning; Angelika N Christ; Craig Nourse; Stephen Kazakoff; Darrin Taylor; Conrad Leonard; David K Chang; Marc D Jones; Michelle Thomas; Clare Watson; Mark Pinese; Mark Cowley; Ilse Rooman; Marina Pajic; Giovanni Butturini; Anna Malpaga; Vincenzo Corbo; Stefano Crippa; Massimo Falconi; Giuseppe Zamboni; Paola Castelli; Rita T Lawlor; Anthony J Gill; Aldo Scarpa; John V Pearson; Andrew V Biankin; Sean M Grimmond Journal: Int J Cancer Date: 2014-05-09 Impact factor: 7.396
Authors: Norma E Ramirez; Zhonghua Zhang; Aasakiran Madamanchi; Kelli L Boyd; Lynda D O'Rear; Abudi Nashabi; Zhengzi Li; William D Dupont; Andries Zijlstra; Mary M Zutter Journal: J Clin Invest Date: 2010-12-06 Impact factor: 14.808
Authors: Andrei P Drabovich; Maria P Pavlou; Christina Schiza; Eleftherios P Diamandis Journal: Mol Cell Proteomics Date: 2016-04-11 Impact factor: 5.911
Authors: Silvia A Teixeira; Regislaine V Burim; Mariano S Viapiano; Lucas T Bidinotto; Suely K Nagashi Marie; Suzana M Fleury Malheiros; Sueli M Oba-Shinjo; Augusto F Andrade; Carlos G Carlotti Journal: Front Oncol Date: 2022-07-22 Impact factor: 5.738